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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
Methylcobalamin alone or in combination with Lidocaine is clinically more effective than
Lidocaine alone in relieving Herpes Zoster related neuropathic pain with subcutaneous
injections.
STUDY DESIGN: This is a systematic review of three peer-reviewed primary studies. All were
randomized, controlled trials published between the years of 2014 and 2016.
DATA SOURCES: Data sources obtained for this review were published in peer reviewed
journals and selected from PubMed Database.
OUTCOME MEASURED: The outcomes measured reflected the effectiveness of incorporating
subcutaneous Methylcobalamin in the treatment regimen for neuropathic pain in Herpes Zoster
patients. The patients in each study reported their pain at baseline and after treatment using an
11-point NRS to assess a significant change in pain.
RESULTS: All three studies conducted showed significant improvement in Herpes Zoster
related neuropathic pain for the participants whose treatment regimen included subcutaneous
Methylcobalamin injections.
CONCLUSIONS: The evidence presented in this review is conclusive that the use of
subcutaneous injections of Methylcobalamin in the treatment of Herpes Zoster related
neuropathic pain is significantly more effective than Lidocaine alone.
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INTRODUCTION
Herpes Zoster (HZ), commonly known as Shingles, is a condition caused by the
reactivation of the latent varicella zoster virus (VZV). The virus initially causes the condition
known as Chicken Pox and lies dormant in the dorsal root ganglia after recovery. With viral
reactivation, HZ is characterized by vesicles, pruritis, and neuropathic pain in a unilateral
dermatomal distribution of the affected nerve.1,2,3 The disease generally lasts between 7-10 days,
while the skin may take 2-4 weeks to return to normal. The most common complication of HZ is
postherpetic neuralgia (PHN), pain that persists after the rash has subsided. Although
reactivation is usually benign in children, the pain can be debilitating when HZ presents in
adults.4 Most patients who experience PHN will have resolution within a few weeks or months.
However, some people will have pain that persists for years with significant interference with
their daily life.5
In order to prevent HZ and the associated PHN complications, the VZ vaccine was
released for use in the United States in 1995. However, prior to the vaccine availability, almost
all persons were susceptible to infection of VZV. According to the CDC, thirty percent of the
current US population will have a reactivation of VZV in their lifetime, leading to significant
morbidity annually. Incidence rates have shown to increase with age, the highest being in the
sixth decade and beyond. Though uncommon to have more than one episode, recurring
reactivations of VZV have been correlated with immunocompromised states, such as individuals
with AIDs or certain cancers like leukemia.4,5,6
It is estimated that the United States has one million HZ cases annually. Though a
majority of these patients can be followed and treated through routine outpatient visits, according
to the Center of Disease Control and Prevention (CDC), one to four percent of these HZ patients
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are hospitalized due to complications. Approximately thirty percent of those hospitalized are
immunocompromised. According to a recent study reported by the CDC, HZ is the underlying
cause of 96 deaths on average each year.5 In 2004, the United States’ economic burden of HZ
related healthcare was estimated to be $1.9 billion annually. 8 With routine varicella
immunizations, administration of prophylaxis, and action in removing susceptible personnel
from possible exposures, national costs involved with postherpetic complications have and will
continue to be cut down.7
Although specific populations such as the elderly and immunocompromised are known to
be at a higher risk for developing HZ, the exact cause of the reactivation of VZV is unknown.5
Therefore, it is pertinent to find the most effective treatment for HZ and its complications. To
shorten the length and lessen the severity of the illness, antiviral therapy including acyclovir,
valacyclovir, and famciclovir are available. Therapy should be administered as soon as possible
after the rash has appeared. In order to prevent secondary infection, antibiotics can be given.
Symptomatic relief can be managed with analgesics, wet compresses, or calamine lotion.
Neuropathic pain treatment currently includes local lidocaine, anticonvulsants, TCAs, and
cryotherapy.6
As the risk of HZ increases with age, the risk of developing neuropathic pain increases as
well, experienced by 10-30% of these patients.5 Although the symptoms usually resolve within
weeks to months, the pain can last up to years in select patients. Due to the severe interference
with daily life, it should be evaluated if there are more effective treatments to prevent the painful
complications of HZ. Clinical use of Methylcobalamin (MeB12) therapy has shown to improve
symptoms of peripheral neuropathy and autonomic dysfunction.1 It is proposed that including
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local injections of Methylcobalamin into the treatment regimen of PHN could improve the HZ
patients’ neurological response.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not
Methylcobalamin alone or in combination with Lidocaine is clinically more effective than
Lidocaine alone in relieving HZ related neuropathic pain with subcutaneous injections.
METHODS
The studies utilized in this systematic review included three randomized controlled
studies. The populations were comprised of patients with HZ related neuropathic pain, including
acute herpetic neuralgia (AHN) and acute ophthalmic herpetic neuralgia (AOHN). The studies
evaluated the use of subcutaneous (SC) injection of MeB12 in the treatment regimen to improve
neuropathic pain of the populations. The intervention used in the first study was SC injection
MeB12 alone1 while the other two studies’ intervention was SC MeB12 combined with SC
Lidocaine. 2,3 These populations were compared to controlled groups given SC injection of
Lidocaine alone1 and SC injection of Lidocaine plus IM injection of MeB12. 2,3 The
demographics and characteristics of the studies are shown in Table 1.
The keywords “herpes zoster” or “shingles”, “lidocaine”, and “vitamin” were searched to
locate sources from PubMed Database. The articles were chosen based off of relevance to the
clinical question and included outcomes that were patient oriented (POEMS). Inclusion criteria
required studies that were RCTs or other primary research studies and studies that were
published after 2007. Exclusion criteria included studies using populations with neuropathic pain
not related to HZ or medication interventions administered by a route other than SC injections.
All articles were published in English, in peer-reviewed journals, between the years 2014-2016.
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The statistics reported included Relative Benefit Increase (RBI), Absolute Benefit Increase
(ABI), Number Needed to Treat (NNT), and 95% Confidence Interval (CI).
Table 1: Demographics & Characteristics of Included Studies
Study

Type

# Pts

Inclusion Criteria

Exclusion Criteria

40

Age
(yrs)
>25

Xu1,
2014

Single
center,
RCT

Herpes Zoster dx
lasting 20-180
days.
Experienced
cutaneous or/and
subcutaneous itch
and/or pain in the
skin.

Single
center,
observerblind,
RCT

49

>50

Single
center,
observerblind,
RCT

89

>50

AOHN 4-7 days
after onset of
vesicles with pain,
>5 lesions, and
swelling. Worse
pain score ≥ 6 in
past 24 hrs. U/L
rash on forehead,
vertex, eyebrow,
side of nose, or
regions adjacent.
AHN 4-7 days after
onset of vesicles
with pain and > 25
lesions. Worst pain
score > 6 in past 24
hrs.
U/L rash within
T5-10 dermatome.

U/L itch for < 20 days or
outside vesicular region.
Any significant medical
condition.
Hypersensitivity to
thiamine or cobalamin.
Use of supplement with
vitamin B.
Cognitive impairment.
Topical analgesics or
nerve blocker use < 10
days before the baseline.
U/L pain in vesicular
region > 7 days after
rash onset.
Pain outside the V1
regions.
Any significant medical
condition.
Cognitive impairment.

Xu2,
2016

Xu3,
2016

U/L pain in vesicular
region > 7 days after
rash onset.
Pain outside the target
regions.
Steroid, analgesics, or
capsaicin use within 4
weeks of study entry.
Any significant medical
condition.
Cognitive impairment.

W/
D
5

Interventions

1

SC combo of
MeB12 1000 g
and 20 mg
lidocaine (2.0
mL) VS. IM
MeB12 plus SC
lidocaine
- daily in
morning, 6
days/week for 2
weeks
SC combo of
MeB12 1000 g
and 20 mg
lidocaine (2.0
mL) VS. IM
MeB12 plus SC
lidocaine
- daily in
morning, 6
days/week for 2
weeks

3

MeB12 1000 g
VS. 1.0%
Lidocaine
30mg/3.0mL
- SC daily in
morning, 6
days/week for 4
weeks

OUTCOMES MESURED
Outcomes measured were those of patient-oriented evidence that matters (POEMS). Each
study used an 11-point numeric rating scale (NRS) (0 = pain, 10 = most painful sensation
imaginable) to measure the level of neuropathic pain per the patient. The NRS was used at
baseline and at the end of treatment to measure the extent of pain relief with intervention. Xu1
baseline was the worst pain over the past 24 hours on the day previous to treatment. Xu 2 and Xu3
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baseline was the worst pain since rash onset. Xu1 endpoint was the worst pain over the past 24
hours on day 28 of treatment. Xu2 and Xu3 endpoint was the worst pain during the past 24 hours
on day 14 of treatment.
RESULTS
This review analyzed three randomized controlled studies to assess if the use of SC
MeB12 would improve relief of HZ related neuropathic pain as compared to SC Lidocaine alone.
Each study compared a treatment regimen that included SC MeB12 to a controlled treatment
regimen with only SC Lidocaine. All three studies used dichotomous data.
In the study conducted by Xu et al,1 92 participants were assessed for eligibility.
Inclusion criteria were as follows: a confirmed diagnosis of HZ lasting > 20 days, age > 25 years,
having pain/itch in the area associated with the HZ rash, and a worst itch NRS score of > 4 in the
past 24 hours.1 This study was looking at relief of itch symptoms as well as pain. Postherpetic
itch is not effected by increased age like PHN is, therefore, this study included younger
participants than other studies observing only PHN. Exclusion criteria were as follows: HZ rash
lasting < 20 days, neuropathic itch outside the target regions, any clinically significant medical
condition or severe general disease, cognitive impairment, hypersensitivity to cobalamin, use of
vitamin B-containing supplements, and use of topical analgesics or nerve blockers in target
region within 10 days before the baseline visit.1 The final two exclusion criteria were mentioned
to prevent alteration of reported pain scores. The exclusion of those with HZ < 20 days was to
prevent the healing or the loss of scabs altering the sensations (itch and pain) measured.
After removing participants that did not meet criteria, declined to participate, or other
reasons, 80 participants were left to be randomized by computer generation and distributed into 4
groups. For the purpose of this review, only two groups, B12 (n =20) and LD (n =20) were
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observed. The B12 group received SC injections of MeB12, while the LD group received SC
1.0% lidocaine injections, into the regions of crusted lesions where the patients experienced
itching and pain. Frequency of dosing was once daily every morning, 6 times per week for 4
weeks. The patients were observed for the following hour and discharged without symptoms of
discomfort. The patients’ NRS pain score was measured from baseline to days 7, 14, and 28 of
treatment.1 For the purpose of this review, only baseline and day 28 were observed, assessing for
improvement to a pain score < 3.
Compliance was measure by the treating physician by recording the number of treatment
sessions attended by each patient and the number of missed or canceled appointments. Three
patients were discontinued by the investigator for noncompliance. Two others dropped out due to
lack of improvement and rapid pain quenched. A total of 5 out of 40 participants (2 of group B12
and 3 of group LD) dropped out of this study.1
At baseline, the control and intervention groups had similar mean pain scores. Group B12
had a mean pain score of 6.65, while group LD had a mean pain score of 6.60. After a treatment
period of 28 days, 65% of group B12 reported an improved pain score < 3. In contrast, 0% of
group LD reported a pain score < 3.1 By calculating the NNT to be 2 patients, these results are
significant. It can be concluded that local MeB12 injection provided a significant reduction in
HZ neuropathic pain compared to local 1% lidocaine injection.
Table 2: Pain NRS score at baseline and endpoint of intervention and control group, Xu 1
Xu1

Mean pain NRS at
Baseline

% of Pts with pain NRS < 3 at
28-Day Endpoint

RBI

ABI

NNT

Intervention:
SC B12
Control:
SC Lido

6.65 (SD 0.88)

0.65

1.00

6.5

2 patients
(CI n/a)

6.60 (SD 1.35)

0.0
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In the study conducted by Xu et al,2 106 participants were assessed for eligibility.
Inclusion criteria were as follows: AOHN < 7 days after rash onset, >5 lesions on rash, aged >50
years, severe pain in the region associated with the HZ rash, a worse pain score > 6 in the
previous 24 hours, and willingness to comply with the allocated treatment and follow-up
measurements. This study included participants at an older age than Xu 1 because HZ neuropathic
pain increases significantly with age. Exclusion criteria were as following: pain > 7 days after
rash onset, neuropathic or significant pain outside the V1 regions, any clinically significant
medical condition or laboratory abnormality, and cognitive impairment. 2
After meeting criteria, 98 participants enrolled in the study and were randomized by
computer generation and distributed into control and intervention groups. Those were separated
out into 4 total groups based on rash onset, a control and intervention group with onset < 3 days
and a control and intervention group with onset between 4-7 days. For the purpose of this review,
only the latter two groups were observed, B0 (n =25) and B1 (n =24). The B0 control group
received IM MeB12 and SC lidocaine injections, while the B1 intervention group received a
combination SC injection of MeB12 and lidocaine, into the subcutaneous regions of the affected
V1 innervations where the patients experienced pain. Frequency of dosing was once daily every
morning, 6 times per week for 2 weeks. The patients were observed for the following hour and
discharged without symptoms of discomfort. The patients’ NRS pain score was measured at
baseline and each day of treatment.2 For the purpose of this review, only baseline and day 14
were observed, assessing for improvement to a pain score < 3.
Due to lack of improvement after 8 days of treatment, only one participant from B 0
control group dropped out of the study. A total of 1 out of 49 participants (from group B0 and B1)
were lost.2
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At baseline, the control and intervention groups had the same mean pain scores at 8.0.
After a treatment period of 14 days, 96% of group B1 reported an improved pain score < 3. In
contrast, 16% of group B0 reported a pain score < 3.2 By calculating the NNT to be 2 patients
along with a CI of 1.03-1.58, these results are significant. It should be noted that the 16% with
group B0 is a similar rate to the known history of the natural decline of pain in HZ. This makes it
difficult to prove any benefits of using IM MeB12. It can be concluded that the combination SC
injection with MeB12 provides a significant reduction in HZ neuropathic pain, in contrast to the
use of IM MeB12 with SC Lidocaine that showed little benefit to the patients.
Table 3: Pain NRS score at baseline and endpoint of intervention and control group, Xu 2
Xu2

Mean pain NRS at
Baseline

% of Pts with pain NRS < 3
at 14-Day Endpoint

RBI

ABI

NNT

B1 Intervention:
SC Combo B12 + Lido
B0 Control:
IM B12 + SC Lido

8.0 (SD 1.0)

0.96

5.00

0.8

8.0 (SD 1.2)

0.16

2 patients
(CI
1.03-1.58)

In the study conducted by Xu et al,3 204 participants were assessed for eligibility.
Inclusion criteria were as follows: AHN from the 5th – 10th intercostal nerve < 7 days after rash
onset; >25 lesions on rash; aged > 50 years; severe pain on the unilateral T5-10 dermatome
associated with the HZ rash and a worst pain score of > 6 in the past 24 hours; and willingness to
comply with the allocated treatment and follow-up measurements.3 Exclusion criteria were as
follows: pain > 7 days after rash onset; neuropathic or significant pain outside the target regions;
use of steroid, analgesics, or capsaicin within 4 weeks of study entry; any clinically significant
medical condition or laboratory abnormality; and cognitive impairment.3
After meeting criteria, 180 participants enrolled in the study and were randomized by
computer generation and distributed into control and intervention groups. Those were separated
out into 4 total groups based on rash onset, a control and intervention group with onset < 3 days
and a control and intervention group with onset between 4-7 days. For the purpose of this review,
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only the latter two groups were observed, ES-Ctl (n =44) and ES-Tr (n =45). The ES-Ctl group
received IM MeB12 and SC lidocaine injections, while the ES-Tr group received a combination
SC injection of MeB12 and lidocaine, into the subcutaneous regions of the crusted lesions where
the patients experienced pain. Frequency of dosing was once daily, 6 times per week for 2
weeks. The patients were observed for the following hour and discharged without symptoms of
discomfort. The patients’ NRS pain score was measured at baseline and each day of treatment. 3
For the purpose of this review, only baseline and day 14 were observed, assessing for
improvement to a pain score < 3.
Due to lack of improvement after receiving treatment for 8 days, one patient in the ES-Ctl
group did not complete the study. One other participant of this group was lost to follow up after
receiving 10 days of treatment. In the ES-Tr group, one subject dropped out because of a leg
fracture. A total of 3 out of 89 participants (2 of group ES-Ctl and 1 of group ES-Tr) dropped out
of this study.3
At baseline, the control and intervention groups had similar mean pain scores. Group ESTr had a mean pain score of 8.4, while group ES-Ctl had a mean pain score of 8.3. After a
treatment period of 14 days, 96% of group ES-Tr reported an improved pain score < 3. In
contrast, 13% of group ES-Ctl reported a pain score < 3.3 By calculating the NNT to be 2
patients along with a CI of 1.06-1.43, these results are significant. It can be concluded that the
combination SC injection with MeB12 provides a significant reduction in HZ neuropathic pain,
in contrast to the use of IM MeB12 with SC Lidocaine that showed little benefit to the patients.
Table 4: Pain NRS score at baseline and endpoint of intervention and control group, Xu 3
Xu3

Mean pain NRS at
Baseline

% of Pts with pain NRS < 3
at 14-Day Endpoint

RBI

ABI

NNT

ES-Tr Intervention:
SC Combo B12 + Lido

8.4 (SD 1.5)

0.96

6.38

0.83

2 patients
(CI
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ES-Ctl Control:
IM B12 + SC Lido

8.3 (SD 1.2)

0.13

1.06-1.43)

Safety and Tolerability
The injections were well tolerated overall across all studies. There were no serious
injuries or adverse events noted during the interventions or during the follow up periods.1,2,3
DISCUSSION
The results from all studies suggest that treatment for HZ neuropathic pain could be
improved by using SC MeB12 injections. Xu1 showed significant improvement with SC MeB12
as opposed to SC Lidocaine. Similarly, Xu2 and Xu3 showed significant improvement with SC
combination of MeB12 and Lidocaine as opposed to IM MeB12 and SC Lidocaine.
Due to the increase in pain severity that is corelated with the increased age of patients, it
is understandable for Xu2 and Xu3 to use only participants older than 50 years of age. With Xu1
observing patients as young as 25 years old, incorporation of this study’s results into this review
could provide a stronger idea of the effect MeB12 has on all ages.
If the treatment regimens used in these three studies were to be implemented in routine
HZ treatment, patients would be required to receive injections 6 days per week for several
weeks. This could pose an obstacle if patients have difficulty acquiring insurance. A more
affordable solution could be to administer treatment during nurse visits. Depending on
medication regulations, the patients can also be taught how to administer the injections at home
to save them time and money on daily visits to the office.
Methylcobalamin is a common supplement, vitamin B12, taken over the counter.
Although the recommended daily dose for adults is 2.4 micrograms, the body will only use what
it needs, allowing the kidneys to excrete any excess. In the rare cases of patients with vitamin B 12
deficiencies, high doses of the supplement can cause dizziness, headaches, anxiety, nausea, or
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vomiting. The most common cause of deficiency is from vegetarian diets. Possible interactions
with other medications causes decreased absorption of the supplement. 9
Limitations
Limitations to the studies used involve the participants. Although the amounts of patients
that dropped out were small, they still had a significant effect in combination with the small
sample size of participants. A larger number of patients would need to be used in future studies
to make up for the dropout rates as well as to confirm the findings of these three studies. The
authors believed that a limitation in their studies was in the treatment administration. The
difficulty in blinding the local treatment injections could have had a negative effect on the
results.1,2 Additional treatment limitations involve the dosing of the medications. Xu et al1 states
that the dosing recommendations were based off of limited data. More studies need to be
conducted to find the optimal dosing for treating PHN. Restrictions were also found in
quantifying the pain by participants. The NRS pain scale can be subjective and difficult to
regulate. Xu2 states that there was concern with patients reporting their pain scores over the
phone. The authors believed that pain perception may be different or even more accurate during
routine monitoring visits.
CONCLUSION
The evidence presented in this review is conclusive that including SC injections of
MeB12 in the treatment regimen of HZ related neuropathic pain is clinically more effective than
SC lidocaine injections alone. In future studies, it would be beneficial to extend the follow up
period to ensure the efficacy of treating with SC MeB12 and confirm the lack of side effects. In
order to improve pain scores even further, it may be advantageous to experiment with nerve
block techniques with lidocaine and MeB12, rather than only subcutaneous injections, to involve
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the full nerve track affected. Clinical use of MeB12 therapy has already shown to improve
symptoms of peripheral neuropathy and autonomic dysfunction. 1 The results of this review have
now supported that local injections of MeB12 allows direct contact with the virus-damaged
tissue to provide a neurological improvement. With continued studies to support these results,
HZ patients in the future will benefit immensely.
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